PR-171 (Carfilzomib): Selectivity & Specificity
PR-171 (Carfilzomib) is a potent inhibitor of 20S immunoproteasome (iCP) (8.1 nM), 20S proteasome β5 subunit (6 nM), 20S proteasome β1 subunit (2400 nM), 20S proteasome β2 subunit (3600 nM), 20S proteasome catalytic subunit β1 (2400 nM), 20S proteasome catalytic subunit β2 (3600 nM), 20S proteasome catalytic subunit β5 (6 nM), 20S proteasome, 20S proteasome (chymotrypsin-like activity), Proteasome β5 subunit (CT-L activity) (6 nM), Proteasome β1 subunit (C-L activity) (2400 nM), Proteasome β2 subunit (T-L activity) (3600 nM), Relapsed/refractory multiple myeloma, Glioblastoma, Lung cancer, Refractory renal cancer, Metastatic prostate cancer, VD, CVAE, Cardiac failure, Ischemic heart disease, Hypertension, AF, CAD, TMA. PR-171 (Carfilzomib) exhibits the greatest inhibitory potency toward 20S proteasome β5 subunit (IC50 = 6 nM).